Plain-English translation of NCT05852041 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is testing whether a new imaging scan called rhPSMA-73 PET-MRI can better detect aggressive forms of prostate cancer in men who have been diagnosed with early-stage disease. The scan works by injecting a special tracer that highlights cancer cells, then taking detailed pictures. Researchers want to see if this imaging method can catch more dangerous cancers that might otherwise be missed.
Many men with early-stage prostate cancer are safely monitored without immediate treatment (called active surveillance), but some have more aggressive cancer hiding that should be treated sooner. This trial aims to find a better way to identify which men actually need treatment rather than waiting, so doctors and patients can make smarter decisions about care.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the imaging tracer, then have two detailed scans of your prostate (a PET-MRI scan and a standard MRI scan). You will also have a genetic test done on tissue from your previous biopsy. Within 90 days of your scans, you'll undergo either an MRI-guided biopsy or prostate surgery as part of your normal care—the study will compare the imaging results to what the biopsy or surgery finds. The entire process takes place over roughly 3 months.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States